Studies have confirmed that the pro-apoptotic gene BAX is significantly downregulated in pancreatic cancer cells with GEM acquired resistance and that the ratio of BAX/BCL-2 can predict GEM sensitivity. This evidence concerns the gene BCL2 and familial pancreatic carcinoma.